Ardelyx (NASDAQ: ARDX) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Ardelyx to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Insider & Institutional Ownership

78.6% of Ardelyx shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 15.5% of Ardelyx shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Ardelyx and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ardelyx N/A -62.60% -56.57%
Ardelyx Competitors -4,766.74% -354.83% -43.39%

Earnings & Valuation

This table compares Ardelyx and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Ardelyx N/A -$113.62 million -2.27
Ardelyx Competitors $464.68 million $167.54 million -6.72

Ardelyx’s peers have higher revenue and earnings than Ardelyx. Ardelyx is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Ardelyx and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ardelyx 0 0 5 0 3.00
Ardelyx Competitors 1377 4466 12292 311 2.63

Ardelyx presently has a consensus target price of $15.60, indicating a potential upside of 181.08%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.47%. Given Ardelyx’s stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than its peers.

Volatility and Risk

Ardelyx has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Ardelyx’s peers have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.

Ardelyx Company Profile

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company’s cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Receive News & Stock Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related stocks with our FREE daily email newsletter.